Phaseline

Companies › Gateway Institute for Brain Research

Gateway Institute for Brain Research: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
INS-GSH
Intranasal insulin and glutathione combination
INS, GSSPhase 2Parkinson DiseaseSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05266417INS-GSHPhase 2Parkinson DiseaseNeurologySep 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

INS (1) GSS (1)

Companies with the same targets

Elgan Pharma Gan & Lee Pharmaceuticals. Portal Diabetes

Companies built like this

Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.